These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

48 related articles for article (PubMed ID: 16379885)

  • 1. Meta-analysis suggests regression of left ventricular hypertrophy during antihypertensive treatment is linked to reduced risk of cardiovascular disease.
    Evid Based Cardiovasc Med; 2004 Mar; 8(1):22-3; discussion 24-5. PubMed ID: 16379885
    [No Abstract]   [Full Text] [Related]  

  • 2. Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE study.
    Olsen MH; Wachtell K; Ibsen H; Lindholm LH; Dahlöf B; Devereux RB; Kjeldsen SE; Oikarinen L; Okin PM;
    J Hypertens; 2006 Apr; 24(4):775-81. PubMed ID: 16531808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study.
    Wachtell K; Okin PM; Olsen MH; Dahlöf B; Devereux RB; Ibsen H; Kjeldsen SE; Lindholm LH; Nieminen MS; Thygesen K
    Circulation; 2007 Aug; 116(7):700-5. PubMed ID: 17664372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Left bundle branch block and cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension study.
    Li Z; Dahlöf B; Okin PM; Kjeldsen SE; Wachtell K; Ibsen H; Nieminen MS; Jern S; Devereux RB
    J Hypertens; 2008 Jun; 26(6):1244-9. PubMed ID: 18475164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Left ventricular hypertrophy in patients on hemodialysis: importance of anemia].
    Stojimirović B; Petrović D; Obrenović R
    Med Pregl; 2007; 60 Suppl 2():155-9. PubMed ID: 18928184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tissue angiotensin-converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: a pooled meta-analysis of randomized placebo-controlled clinical trials.
    Saha SA; Molnar J; Arora RR
    Diabetes Obes Metab; 2008 Jan; 10(1):41-52. PubMed ID: 18095949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].
    Cases Amenós A; Goicoechea Diezhandiño M; de Alvaro Moreno F
    Nefrologia; 2008; 28 Suppl 3():39-48. PubMed ID: 19018737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regression of left ventricular hypertrophy in hypertensive elderly patients with carvedilol.
    Verza M; Ammendola S; Cambardella A; Scoti G; Vescio S; Tortoriello R; Amato L; Cerqua G; Varricchio G
    Arch Gerontol Geriatr; 1996; 22 Suppl 1():143-7. PubMed ID: 18653022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of changes in the electrocardiographic strain pattern during antihypertensive treatment: the Losartan Intervention for End-Point Reduction in Hypertension Study (LIFE).
    Okin PM; Oikarinen L; Viitasalo M; Toivonen L; Kjeldsen SE; Nieminen MS; Edelman JM; Dahlöf B; Devereux RB;
    Circulation; 2009 Apr; 119(14):1883-91. PubMed ID: 19332468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tissue ACE inhibitors for secondary prevention of cardiovascular disease in patients with preserved left ventricular function: a pooled meta-analysis of randomized placebo-controlled trials.
    Saha SA; Molnar J; Arora RR
    J Cardiovasc Pharmacol Ther; 2007 Sep; 12(3):192-204. PubMed ID: 17875946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of paroxysmal atrial fibrillation depending on the regression of left ventricular hypertrophy in arterial hypertension.
    Hennersdorf MG; Schueller PO; Steiner S; Strauer BE
    Hypertens Res; 2007 Jun; 30(6):535-40. PubMed ID: 17664857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Hypertension and the heart].
    Wachtell K; Andersen NH; Svendsen TL
    Ugeskr Laeger; 2009 Jun; 171(25):2113-6. PubMed ID: 19671394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study.
    Okin PM; Devereux RB; Gerdts E; Snapinn SM; Harris KE; Jern S; Kjeldsen SE; Julius S; Edelman JM; Lindholm LH; Dahlöf B;
    Circulation; 2006 Mar; 113(12):1588-96. PubMed ID: 16534012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Microalbuminuria].
    Olsen MH; Ibsen H; Mogensen CE
    Ugeskr Laeger; 2009 Jun; 171(25):2097-100. PubMed ID: 19671389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Left ventricular hypertrophy and clinical outcomes in hypertensive patients.
    Ruilope LM; Schmieder RE
    Am J Hypertens; 2008 May; 21(5):500-8. PubMed ID: 18437140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beta2-adrenergic receptor polymorphisms and treatment-induced regression of left ventricular hypertrophy in hypertension.
    Iaccarino G; Izzo R; Trimarco V; Cipolletta E; Lanni F; Sorriento D; Iovino GL; Rozza F; De Luca N; Priante O; Di Renzo G; Trimarco B
    Clin Pharmacol Ther; 2006 Dec; 80(6):633-45. PubMed ID: 17178264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Left ventricular (LV) geometry and dipping state are determinants of LV mass reduction with angiotensin-converting enzyme inhibitor antihypertensive treatment.
    Aznaouridis KA; Vyssoulis GP; Karpanou EA; Marinakis AG; Barbetseas JD; Zervoudaki AI; Cokkinos DV; Stefanadis CI
    Blood Press Monit; 2007 Apr; 12(2):87-94. PubMed ID: 17353651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE study.
    Okin PM; Wachtell K; Kjeldsen SE; Julius S; Lindholm LH; Dahlöf B; Hille DA; Nieminen MS; Edelman JM; Devereux RB
    Circ Arrhythm Electrophysiol; 2008 Dec; 1(5):337-43. PubMed ID: 19808428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term risk of diabetes, hypertension and left ventricular hypertrophy associated with the metabolic syndrome in a general population.
    Mancia G; Bombelli M; Facchetti R; Madotto F; Corrao G; Trevano FQ; Giannattasio C; Grassi G; Sega R
    J Hypertens; 2008 Aug; 26(8):1602-11. PubMed ID: 18622239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Roles of cyclooxygenase-2 and phosphorylated Akt (Thr308) in cardiac hypertrophy regression mediated by left-ventricular unloading.
    Wohlschlaeger J; Schmitz KJ; Palatty J; Takeda A; Takeda N; Vahlhaus C; Levkau B; Stypmann J; Schmid C; Schmid KW; Baba HA
    J Thorac Cardiovasc Surg; 2007 Jan; 133(1):37-43. PubMed ID: 17198778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.